BLAINTRAVENOUSVIALPriority Review
Approved
Feb 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
AVASTIN (bevacizumab) by Roche is vascular endothelial growth factor-directed antibody interactions [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2004.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVASTIN (bevacizumab) is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) to block tumor blood vessel formation. It is used across multiple cancer indications and some ophthalmologic conditions, primarily as an adjunct to chemotherapy or other targeted agents. The drug works by starving tumors of their blood supply, slowing disease progression and improving survival in responsive patient populations.
$0.012BPart D
LOE ApproachingDeclining
As AVASTIN approaches loss of exclusivity with strong biosimilar competition, the brand team is likely contracting; focus shifts to defending market share and managing transition strategy rather than growth.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma
Started Dec 2026
10 enrolled
GBM
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Started Jul 2026
688 enrolled
Platinum-Sensitive Ovarian CancerOvarian Cancer
SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer
Started Jun 2026
58 enrolled
Colorectal Neoplasms
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
Started Jun 2026
40 enrolled
Hepatocellular Carcinoma
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
Started May 2026
41 enrolled
Phase 1SAR445877FOlfox6+4 more
Worked on AVASTIN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.